康缘药业创始人提前离任董事长，企业近年掉队明显

Core Viewpoint - The sudden resignation of Chairman Xiao Wei from Kangyuan Pharmaceutical has raised industry concerns, as he was a long-standing leader and founder of the company, having served for over 20 years [1][2][3] Company Leadership Changes - Xiao Wei resigned as Chairman on June 20, 2023, but will continue to serve as a board member and committee member [1] - His term was expected to end on June 25, 2026, indicating an unexpected early departure [2] - Gao Haixin has been appointed as the new legal representative of the company, with a background in engineering and various roles within Kangyuan since 2014 [3] Market Reaction - Following the announcement of Xiao Wei's resignation, Kangyuan Pharmaceutical's stock opened lower on June 23 but stabilized, closing at 14.93 yuan per share, a 1.36% increase, with a market capitalization of approximately 8.453 billion yuan [2] Company Background - Kangyuan Pharmaceutical is recognized as one of the leading modern traditional Chinese medicine companies in China, having developed 57 new traditional Chinese medicine products [4] - The company was established from the Lianyungang Traditional Chinese Medicine Processing Plant and went public in 2002 [4] Financial Performance - Kangyuan Pharmaceutical reported a revenue of 3.898 billion yuan for 2024, a year-on-year decrease of 19.86%, with net profit and adjusted net profit also declining by 15.58% and 27.29%, respectively [7] - The company has experienced significant revenue fluctuations over the past decade, with peak revenue nearing 5 billion yuan and net profit exceeding 500 million yuan [7]